<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143222" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nintedanib</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gole</surname>
            <given-names>Shrey</given-names>
          </name>
          <aff>Northwestern Medicine McHenry Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bankole</surname>
            <given-names>Adegbenga</given-names>
          </name>
          <aff>VTC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shrey Gole declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adegbenga Bankole declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143222.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nintedanib is a small molecule tyrosine kinase inhibitor that binds to growth factor receptors, inhibiting the proliferation of fibroblasts. This action reduces ongoing fibrotic processes and delays the progression to long-lasting damage. Nintedanib is indicated for treating idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and progressive phenotype interstitial lung disease. This activity reviews the indications, contraindications, and adverse events associated with nintedanib therapy. The&#x000a0;activity&#x000a0;also covers the administration, pharmacokinetics, and relevant interactions of nintedanib, providing knowledge crucial for tailoring treatment to individual patient needs.</p>
        <p>The&#x000a0;discussion underscores the importance of the interprofessional healthcare team, focusing on strategies to minimize adverse reactions while maximizing the effectiveness of the treatment. This educational initiative equips healthcare professionals with the necessary tools to safely and effectively administer nintedanib, promoting individualized care for patients undergoing this therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for nintedanib therapy.</p></list-item><list-item><p>Assess the most common adverse&#x000a0;reactions associated with nintedanib therapy.</p></list-item><list-item><p>Evaluate the mechanism of action of nintedanib.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from nintedanib therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143222&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143222">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-143222.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) that binds to a family of growth factor receptors and prevents the proliferation of fibroblasts.&#x000a0;This medication&#x000a0;impedes the ongoing fibrotic process and delays the progression to long-lasting damage. Nintedanib was initially approved by the U.S. Food and Drug Administration (FDA) in 2014 as a treatment for idiopathic pulmonary fibrosis (IPF).<xref ref-type="bibr" rid="article-143222.r1">[1]</xref>&#x000a0;Subsequently, nintedanib was noted to have antifibrotic effects in animal models of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). Interest in this&#x000a0;antifibrotic property led to clinical trials demonstrating significant slowing of fibrosis in ILD related to systemic autoimmune rheumatic diseases (SARD), including systemic sclerosis.<xref ref-type="bibr" rid="article-143222.r2">[2]</xref>&#x000a0;Study results&#x000a0;also&#x000a0;indicated that nintedanib therapy&#x000a0;slows the decline&#x000a0;of forced vital capacity (FVC).<xref ref-type="bibr" rid="article-143222.r3">[3]</xref>&#x000a0;For patients with IPF, nintedanib significantly improves the absolute change in FVC from baseline compared to placebo.&#x000a0;Nintedanib also demonstrated&#x000a0;greater effectiveness&#x000a0;for patients with a decline in FVC &#x02265;10% compared to placebo.<xref ref-type="bibr" rid="article-143222.r4">[4]</xref></p>
        <p>These lung volume benefits are primarily&#x000a0;observed in patients with the usual interstitial pneumonia (UIP) pattern&#x000a0;and SSc-ILD when nintedanib is combined with mycophenolate mofetil or cyclophosphamide.<xref ref-type="bibr" rid="article-143222.r5">[5]</xref>&#x000a0;Nintedanib may also be prescribed when other therapies are contraindicated. This improvement in patient outcomes led to the 2020 FDA approval of nintedanib for progressive fibrosing ILD and SSc-ILD. Similar improvement in lung volume has also been described in a patient with bleomycin-induced fibrosis&#x000a0;and COVID-19-related pulmonary fibrosis.<xref ref-type="bibr" rid="article-143222.r6">[6]</xref><xref ref-type="bibr" rid="article-143222.r7">[7]</xref>&#x000a0;The&#x000a0;American Thoracic Society (ATS) has issued a conditional recommendation for nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD).<xref ref-type="bibr" rid="article-143222.r8">[8]</xref>&#x000a0;The American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Asociaci&#x000f3;n Latinoamericana de T&#x000f3;rax (ALAT) guidelines recommend nintedanib for patients with progressive pulmonary fibrosis who have failed the standard&#x000a0;treatment for fibrotic interstitial lung disease, other than idiopathic pulmonary fibrosis.<xref ref-type="bibr" rid="article-143222.r8">[8]</xref>&#x000a0;Nintedanib effectively slows disease progression and potentially reduces all-cause mortality in patients with progressive fibrosing interstitial lung diseases (PF-ILDs).<xref ref-type="bibr" rid="article-143222.r9">[9]</xref>&#x000a0;The Living with Pulmonary Fibrosis (L-PF) questionnaire results indicated that nintedanib reduced the worsening of dyspnoea, cough, and the overall impact of progressive pulmonary fibrosis over a 52-week period.<xref ref-type="bibr" rid="article-143222.r10">[10]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Systemic sclerosis-associated interstitial lung disease</p>
          </list-item>
          <list-item>
            <p>Chronic fibrosing interstitial lung diseases (progressive phenotype)&#x000a0;<xref ref-type="bibr" rid="article-143222.r11">[11]</xref><xref ref-type="bibr" rid="article-143222.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143222.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nintedanib is an indolinone derivative that binds to tyrosine kinase receptors. The mechanism of action is thought to involve&#x000a0;the restriction of neoangiogenesis by inhibiting&#x000a0;various&#x000a0;growth factors such as fibroblast growth factor receptor (FGFR),&#x000a0;vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR),&#x000a0;colony-stimulating factor-1-receptor (CSF1R), and&#x000a0;Fms-like tyrosine kinase-3 (FLT3).<xref ref-type="bibr" rid="article-143222.r13">[13]</xref>&#x000a0;This drug was initially&#x000a0;designed to treat&#x000a0;non-small lung cancer. Due to similarities in the growth factors involved in the pathogenesis of this cancer and pulmonary fibrosis,&#x000a0;nintedanib was considered a potential treatment for IPF and was studied.<xref ref-type="bibr" rid="article-143222.r14">[14]</xref> Nintedanib competitively binds to the intracellular adenosine triphosphate (ATP) binding site of the growth factor receptors, preventing autophosphorylation and blocking downstream signaling cascades. Additionally, nintedanib blocks non-receptor tyrosine kinases (eg, Src, Lck) directly, preventing the activation of fibroblasts. As a result, nintedanib ultimately inhibits fibroblast proliferation and migration, effectively attenuating angiogenesis within the lungs. This reduction in fibrosis and angiogenesis helps to impede the&#x000a0;progression of ILD, IPF, and associated complications such as pulmonary hypertension.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> When administered with food,<bold>&#x000a0;</bold>Nintedanib (BIBF&#x000a0;1120) reaches peak plasma concentrations&#x000a0;within 2 to 4 hours. The absolute bioavailability is 4.7% in healthy individuals. The presence of transporters and significant first-pass metabolism reduce absorption and bioavailability. Following food intake, nintedanib exposure increases by roughly 20% compared to fasting conditions, with delayed absorption. The pharmacokinetics of nintedanib are linear, with steady-state plasma levels attained within&#x000a0;1 week.</p>
        <p><bold>Distribution: </bold>Nintedanib exhibits biphasic distribution kinetics. After intravenous infusion, this drug demonstrates a large distribution volume that exceeds the total body volume (V<sub>dss</sub>: 1050 L). In vitro studies reveal that nintedanib is highly protein-bound; 97.8% is bound to serum albumin.<xref ref-type="bibr" rid="article-143222.r15">[15]</xref>&#x000a0;</p>
        <p><bold>Metabolism:&#x000a0;</bold>Nintedanib is primarily metabolized through hydrolytic cleavage by esterases, producing the free acid metabolite BIBF 1202, which is subsequently glucuronidated by UDP-glucuronosyltransferases such as UGT1A1. Only a minor portion of nintedanib undergoes metabolism via cytochrome P450 pathways, predominantly involving CYP3A4, accounting for about 5% of the biotransformation. The drug is mainly excreted via feces, with less than 1% eliminated in urine. Additionally, nintedanib is a substrate and weak inhibitor of P-glycoprotein and a minor substrate of CYP3A4. Patients receiving concomitant P-gp and CYP3A4 inhibitors should be closely monitored.<xref ref-type="bibr" rid="article-143222.r15">[15]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>The&#x000a0;primary route of elimination&#x000a0;is through fecal and biliary excretion, accounting for approximately 93% of the dose. The half-life of nintedanib in patients with idiopathic pulmonary fibrosis is approximately 9.5 hours.</p>
      </sec>
      <sec id="article-143222.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Nintedanib therapy is available in 100 mg and 150 mg soft capsules. The manufacturer recommends that the capsules&#x000a0;be taken whole with food and fluids. Chewing, crushing, or splitting the capsules can cause a bitter taste.&#x000a0;Nintedanib should be stored at room temperature, away from moisture and excessive heat.&#x000a0;The drug should be kept tightly closed in the same container it came in and out of reach from children.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The typical recommended dosage is 150 mg twice daily.&#x000a0;Physicians should consider temporarily reducing the dose to 100 mg, interrupting treatment, or discontinuing the drug if adverse reactions occur. Extra capsules are not recommended to make up for&#x000a0;a missed or skipped dose. Nintedanib should be&#x000a0;disposed of safely, ensuring that children, pets, or other people cannot access the disposed-of capsules.&#x000a0;A medication take-back program at a local pharmacy offers the best option for drug disposal.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>In cases of mild hepatic impairment (Child-Pugh class A), low body mass index (BMI), or persistent gastrointestinal&#x000a0;adverse&#x000a0;effects, a dose reduction to 100 mg twice daily is recommended.<xref ref-type="bibr" rid="article-143222.r16">[16]</xref>&#x000a0;Nintedanib is not advised for patients with moderate or severe hepatic impairment.&#x000a0;</p>
        <p><bold>Renal impairment: </bold>Adjustment of the nintedanib dosage for mild to moderate renal impairment is not needed.&#x000a0;There is no available data regarding&#x000a0;nintedanib&#x000a0;administration for patients with&#x000a0;severe renal impairment (CrCl &#x0003c;30 mL/min) and end-stage renal disease.<xref ref-type="bibr" rid="article-143222.r15">[15]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The use of nintedanib during pregnancy is not recommended.<xref ref-type="bibr" rid="article-143222.r17">[17]</xref>&#x000a0;Nintedanib is a pregnancy category D drug, and females of reproductive age should be counseled to use highly effective contraception&#x000a0;(for example, reversible implantable contraceptive device) before&#x000a0;initiating&#x000a0;and during therapy. Contraception should be continued for at least&#x000a0;3 months after the last dose of nintedanib. A pregnancy test should be performed before and at regular intervals during treatment.&#x000a0;</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>There is no available data on the clinical use of nintedanib during breastfeeding. Since nintedanib is over 97% bound to plasma proteins, the&#x000a0;amount in breast milk is&#x000a0;thought to be minimal. However, given its half-life of approximately 9.7 hours, there is a potential for drug accumulation in the breastfeeding infant. Therefore, it is recommended to avoid breastfeeding during nintedanib therapy.<xref ref-type="bibr" rid="article-143222.r18">[18]</xref></p>
        <p><bold>Pediatric patients: </bold>The safety and efficacy of nintedanib have not been established in the pediatric population.</p>
        <p><bold>Older patients:</bold>&#x000a0;During&#x000a0;clinical trials, the effectiveness and safety of nintedanib were similar across age groups, though increased sensitivity in some older individuals cannot be excluded.</p>
      </sec>
      <sec id="article-143222.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The following adverse reactions are associated with nintedanib administration:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Gastrointestinal:</bold> (most common) nausea, vomiting, diarrhea (76%), abdominal pain (10%), decreased appetite (10%)&#x000a0;<xref ref-type="bibr" rid="article-143222.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Hepatic:</bold> elevation in liver enzymes&#x000a0;<xref ref-type="bibr" rid="article-143222.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Endocrine:</bold> decreased weight (7%)</p>
          </list-item>
          <list-item>
            <p><bold>Respiratory:</bold> nasopharyngitis (7%), cough (14%), upper respiratory tract infection (14%)</p>
          </list-item>
          <list-item>
            <p><bold>Nervous system:</bold> headache (12%), fatigue (14%)</p>
          </list-item>
          <list-item>
            <p><bold>Dermatological:</bold> dermal ulcer (16%)</p>
          </list-item>
          <list-item>
            <p><bold>Genitourinary:</bold> urinary tract infection (12%)&#x000a0;<xref ref-type="bibr" rid="article-143222.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Most diarrheal events were classified as mild to moderate and occurred mainly within the first&#x000a0;3 months of therapy. Patient education and supportive treatment such as adequate hydration, antidiarrheals, and antiemetics should be provided.&#x000a0;A dose reduction or treatment interruption should be considered for patients with persistent gastrointestinal symptoms despite being on supportive treatment, or treatment should be discontinued.<xref ref-type="bibr" rid="article-143222.r16">[16]</xref>&#x000a0;A low BMI is the major risk factor for diarrhea, and adding prednisolone was beneficial. Additionally, low BMI and poor performance status were also significant risk factors for nausea.<xref ref-type="bibr" rid="article-143222.r22">[22]</xref><xref ref-type="bibr" rid="article-143222.r23">[23]</xref>&#x000a0;Elevated alanine transaminase (ALT), aspartate transaminase (AST), and bilirubinemia were commonly seen in patients with low BMI. These adverse effects are particularly common in females, Asians, and&#x000a0;patients who weigh less than 65 kg. The risk of hepatotoxicity is reduced when treated with a&#x000a0;reduced dose of 100 mg twice daily.<xref ref-type="bibr" rid="article-143222.r24">[24]</xref></p>
        <p>Reported post-marketing adverse events include gastrointestinal perforation, proteinuria, and pancreatitis. In several clinical trials, nintedanib was also found to be associated with an increased risk of bleeding, likely secondary to VEGFR inhibition. Although severe bleeding and arterial thromboembolic events such as myocardial infarction (MI) and stroke were rare, bleeding events with severe and fatal outcomes have been reported in the post-marketing surveillance of the drug.<xref ref-type="bibr" rid="article-143222.r17">[17]</xref>&#x000a0;As a result, patients on nintedanib therapy receiving full anticoagulation require close monitoring for adverse bleeding events.<xref ref-type="bibr" rid="article-143222.r25">[25]</xref></p>
        <p>The inhibition of VEGFR and its downstream signaling pathways has been associated with renal dysfunction, including proteinuria and hypertension. The literature review describes several cases of proteinuria and thrombotic microangiopathy related to the chronic use of nintedanib.<xref ref-type="bibr" rid="article-143222.r26">[26]</xref>&#x000a0;The proteinuria was reversible with the discontinuation of nintedanib only in some cases. Interruption of therapy should be considered in cases of new, worsening, or persistent proteinuria.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>P-gp and CYP3A4 inducers:</bold> Precaution should be taken when nintedanib is co-administered with medications metabolized by CYP3A4 and P-glycoprotein enzymes due to altered bioavailability and metabolism.<xref ref-type="bibr" rid="article-143222.r15">[15]</xref>&#x000a0;Some commonly used drugs that may potentially affect nintedanib metabolism include but are not limited to omeprazole, barbiturates, phenytoin, amoxicillin, azithromycin, ketoconazole, carbamazepine, amiodarone, rifampin, and St. John's wort.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anticoagulants:</bold> Nintedanib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, can potentially elevate the risk of bleeding complications. Patients undergoing anticoagulation therapy should be monitored closely for signs of bleeding.<xref ref-type="bibr" rid="article-143222.r4">[4]</xref>&#x000a0;For patients requiring anticoagulant therapy, direct oral anticoagulants (DOACs) may be an option; however, further research is needed.<xref ref-type="bibr" rid="article-143222.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143222.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the FDA-approved labeling, there are no absolute contraindications.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The use of nintedanib during pregnancy and&#x000a0;breastfeeding is not recommended.<xref ref-type="bibr" rid="article-143222.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Moderate to severe hepatic impairment (Child-pugh class B and C) is also a relative contraindication to nintedanib therapy.<xref ref-type="bibr" rid="article-143222.r17">[17]</xref>&#x000a0;Nintedanib is not well-studied in patients with severe hepatic impairment.</p>
          </list-item>
          <list-item>
            <p>Tobacco use is associated with reduced efficacy of nintedanib, as well as worsening of preexisting disease, so patients should be advised to stop smoking before initiating treatment.<xref ref-type="bibr" rid="article-143222.r28">[28]</xref><xref ref-type="bibr" rid="article-143222.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Caution should be exercised when prescribing nintedanib to&#x000a0;women older than 65 with low body mass index (BMI)&#x000a0;or patients with coronary artery disease, thromboembolic events, anticoagulation, recent abdominal surgery, and a history of gastrointestinal perforation.</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity&#x000a0;is&#x000a0;discussed elsewhere (see&#x000a0;Toxicity).<xref ref-type="bibr" rid="article-143222.r20">[20]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143222.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Pregnancy testing before initiating therapy and periodically during the therapeutic course is recommended&#x000a0;for women of reproductive age.&#x000a0;</p>
        <p>A liver function test is necessary at baseline and within the first&#x000a0;3 months of therapy. Afterward, regular monitoring should be performed every 6&#x000a0;to 12 months or as clinically indicated.<xref ref-type="bibr" rid="article-143222.r16">[16]</xref>&#x000a0;Physicians should take precautionary measures in patients at high risk of bleeding and those with a history of arterial thromboembolism. Patients with signs and symptoms of acute coronary syndrome should undergo treatment interruption.<xref ref-type="bibr" rid="article-143222.r30">[30]</xref></p>
        <p>The optimal time to assess treatment response is not well defined. Clinicians should perform routine monitoring with pulmonary function tests (PFT), 6-minute walk tests (6MWT), home spirometry, subjective exercise tolerance, and physical exam findings.<xref ref-type="bibr" rid="article-143222.r31">[31]</xref>&#x000a0;In patients with IPF, physicians assess FVC at baseline and monitor for changes.<xref ref-type="bibr" rid="article-143222.r4">[4]</xref></p>
        <p>Changes in the patient's clinical condition may reflect superimposed infection, malignancy, or even the development of pulmonary artery hypertension and not just the progression of ILD.<xref ref-type="bibr" rid="article-143222.r32">[32]</xref>&#x000a0;Reevaluation of patients should occur if there are changes in the clinical status, which may involve repeating tests such as high-resolution computed tomography (HRCT), other imaging tests, and PFT. Quantitative HRCT is also a sensitive tool used to quantify the disease progression and response to treatment in patients with SSc-ILD.</p>
      </sec>
      <sec id="article-143222.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Nintedanib therapy is frequently associated with elevated liver enzymes and bilirubin, but this is usually reversible with dose reduction or treatment interruption. For patients with ALT/AST elevations of less than 3&#x000a0;to 5 times the upper limit without signs of hepatotoxicity, therapy should be held and resumed at a lower dose of 100 mg twice daily once the liver enzymes normalize. Women with low BMI, low body surface area (BSA),&#x000a0;or Asian ethnicity are at higher risk of hepatotoxicity when treated with&#x000a0;150 mg twice daily. This is reversible with treatment interruption or dose reduction.&#x000a0;If there is no hepatotoxicity,&#x000a0;these patients may also benefit from starting at 100 mg twice daily with dose titration.<xref ref-type="bibr" rid="article-143222.r24">[24]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There are no recommended guidelines for managing a nintedanib overdose. Treatment should be interrupted in these scenarios, and supportive measures should be initiated.&#x000a0;Any patient with a suspected overdose should undergo close monitoring in a healthcare facility. Treatment should be discontinued in patients who develop signs and symptoms of hepatotoxicity with AST/ALT elevation more than 3&#x000a0;to 5 times the normal upper limit.<xref ref-type="bibr" rid="article-143222.r25">[25]</xref></p>
      </sec>
      <sec id="article-143222.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing progressive fibrosing ILD remains challenging for healthcare providers, and these patients have significant unmet needs. ILD can&#x000a0;cause continued deterioration of lung function, reduced exercise tolerance, worsening dyspnea, and cough. These changes can result in reduced health-related quality of life (HR-QOL), increased morbidity and mortality, and some diseases with ILD have a median survival rate as low as 4.5 years.<xref ref-type="bibr" rid="article-143222.r33">[33]</xref><xref ref-type="bibr" rid="article-143222.r34">[34]</xref><xref ref-type="bibr" rid="article-143222.r35">[35]</xref>&#x000a0;</p>
        <p>Over the last decade, anti-fibrotic drugs such as nintedanib and pirfenidone have become emerging therapies for patients with IPF. Other conditions associated with progressive ILD have also shown promising results in slowing the progression of the disease. When used alone or in combination, the safety and tolerability of these medications are well established, although more studies are needed to determine the degree of the potential synergistic effect.<xref ref-type="bibr" rid="article-143222.r36">[36]</xref>&#x000a0;Nintedanib is an anti-fibrotic drug that has been proven to slow the course of progressive ILD, IPF, and SSc-ILD in clinical trial settings. In real-world studies, nintedanib's efficacy and safety profile are acceptable, and the FDA approved its use&#x000a0;for patients with these conditions.<xref ref-type="bibr" rid="article-143222.r37">[37]</xref></p>
        <p>Patient education should be included in the provider's management tool kit. The pros and cons of this therapy and supportive care should be discussed with patients in detail. Adjunctive treatments, including oxygen therapy, should be prescribed to maintain daily activity and prevent or delay the onset of secondary pulmonary hypertension. Pulmonary rehabilitation has been shown to have long-term benefits as it emphasizes the importance of a comprehensive therapeutic approach to fibrotic lung disease.<xref ref-type="bibr" rid="article-143222.r38">[38]</xref>&#x000a0;</p>
        <p>A multidisciplinary team, including a pulmonologist, rheumatologist, cardiologist, and pulmonary rehabilitation medicine specialist, should be involved in patient care to prevent long-term complications. Although more studies are needed, such an approach may delay disease progression and reduce the need for lung transplantation. ILD is also a risk factor for ischemic heart disease.<xref ref-type="bibr" rid="article-143222.r39">[39]</xref>&#x000a0;Studies have shown that nintedanib can lower oxidative LDL-triggered inflammation and senescence, making it a potential therapy for treating atherosclerosis.<xref ref-type="bibr" rid="article-143222.r40">[40]</xref></p>
        <p>Interprofessional teamwork is also essential to optimal patient management and care. In addition to the multidisciplinary physician team, advanced practice providers (NPs and PAs), nursing staff, respiratory therapists, and pharmacists can all contribute from various areas of expertise to manage cases using nintedanib. All interprofessional team members must maintain meticulous records of their interactions and observations with the patient so all team members operate from the same accurate, updated information. If any caregiver notes any concerns or changes in status, they should reach out to the appropriate team member for further evaluation and possible interventions. This interprofessional approach will drive optimal patient outcomes.</p>
        <p>Patients should be encouraged to get approved vaccines against coronavirus, age-appropriate pneumococcal vaccine, and annual influenza vaccine. Continuous exposure to first-hand and second-hand smoking is detrimental and should be discouraged. There is also a strong association between ILD and depression, which is independently related to sleep quality, pain, and forced vital capacity.<xref ref-type="bibr" rid="article-143222.r41">[41]</xref>&#x000a0;Patients with ILD should routinely have screening for depression during follow-up visits. Recent observations suggest that nintedanib may improve functional ability in patients with pulmonary fibrosis secondary to COVID-19 infection.<xref ref-type="bibr" rid="article-143222.r42">[42]</xref>&#x000a0;</p>
        <p>In patients with progressive IPF not amenable to pharmacological therapy, the introduction of advance directives and palliative care should be considered as the prognosis remains guarded.<xref ref-type="bibr" rid="article-143222.r43">[43]</xref>&#x000a0;Prompt initiation of nintedanib from the time of diagnosis of IPF may result in reduced medical costs and hospitalization risk.<xref ref-type="bibr" rid="article-143222.r44">[44]</xref>&#x000a0;Additional studies are needed to fully understand the early initiation of anti-fibrotic therapy and patient outcomes. As explained above, an interprofessional team approach and&#x000a0;excellent&#x000a0;communication among clinicians,&#x000a0;pulmonologists, rheumatologists, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving patient outcomes&#x000a0;related&#x000a0;to&#x000a0;nintedanib.</p>
      </sec>
      <sec id="article-143222.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143222&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143222">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143222/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143222">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-143222.s11">
        <title>References</title>
        <ref id="article-143222.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Aug</month>
            <day>20</day>
            <volume>373</volume>
            <issue>8</issue>
            <fpage>782</fpage>
            <pub-id pub-id-type="pmid">26287867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maillet</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Quesniaux</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Holweg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ryffel</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2014</year>
            <month>May</month>
            <volume>349</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-20</page-range>
            <pub-id pub-id-type="pmid">24556663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Highland</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Gahlemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clerisme-Beaty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tetzlaff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <collab>SENSCIS Trial Investigators</collab>
            </person-group>
            <article-title>Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>27</day>
            <volume>380</volume>
            <issue>26</issue>
            <fpage>2518</fpage>
            <page-range>2518-2528</page-range>
            <pub-id pub-id-type="pmid">31112379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.</article-title>
            <source>BMC Pulm Med</source>
            <year>2024</year>
            <month>Jan</month>
            <day>27</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <pub-id pub-id-type="pmid">38281037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Devaraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SLF</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tetzlaff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coeck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clerisme-Beaty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Quaresma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haeufel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goeldner</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Schlenker-Herceg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <collab>INBUILD Trial Investigators</collab>
            </person-group>
            <article-title>Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>31</day>
            <volume>381</volume>
            <issue>18</issue>
            <fpage>1718</fpage>
            <page-range>1718-1727</page-range>
            <pub-id pub-id-type="pmid">31566307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gundogan</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Taskinlar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arikoglu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balci</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Citak</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Bleomycin-induced Pneumonitis in a Child Treated With Nintedanib: Report of the First Case in a Childhood.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>e500</fpage>
            <page-range>e500-e502</page-range>
            <pub-id pub-id-type="pmid">35200223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lomanta</surname>
                <given-names>JMJ</given-names>
              </name>
              <name>
                <surname>Quinto</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Urquiza</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Santiaguel</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis.</article-title>
            <source>Am J Case Rep</source>
            <year>2022</year>
            <month>Feb</month>
            <day>13</day>
            <volume>23</volume>
            <fpage>e934830</fpage>
            <pub-id pub-id-type="pmid">35152259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montesi</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Macrea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Adegunsoye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Highland</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaner</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scholand</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Volkmann</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Wigley</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Burlile</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ghazipura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2024</year>
            <month>Jan</month>
            <day>15</day>
            <volume>209</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-152</page-range>
            <pub-id pub-id-type="pmid">37772985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2024</year>
            <season>Jan-Dec</season>
            <volume>18</volume>
            <fpage>17534666241232561</fpage>
            <pub-id pub-id-type="pmid">38414439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijsenbeek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Swigris</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kreuter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Suda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rohr</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <collab>INBUILD Trial Investigators</collab>
            </person-group>
            <article-title>Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.</article-title>
            <source>Eur Respir J</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38135442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hague</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulholland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adamali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khin</surname>
                <given-names>AMN</given-names>
              </name>
              <name>
                <surname>Thould</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Connon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Minnis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Murtagh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Toor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naqvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coker</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yazbeck</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garfoot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rivera-Ortega</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stranks</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beirne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rowan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agnew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Aigbirior</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Butcher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zulfikar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kokosi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kouranos</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molyneaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Renzoni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vitri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Nicol</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kular</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wickremasinghe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Grimes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kinsella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Naftel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crawshaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Dosanjh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huntley</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Gatheral</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Plum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bikmalla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muthusami</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>JCL</given-names>
              </name>
              <name>
                <surname>Tsaneva-Atanasova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scotton</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK.</article-title>
            <source>ERJ Open Res</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">38226064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghazipura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mammen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Hon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bissell</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Macrea</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kheir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khor</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>1040</fpage>
            <page-range>1040-1049</page-range>
            <pub-id pub-id-type="pmid">35499854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wex</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pautsch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schnapp</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hostettler</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.</article-title>
            <source>Eur Respir J</source>
            <year>2015</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>1434</fpage>
            <page-range>1434-45</page-range>
            <pub-id pub-id-type="pmid">25745043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vancheri</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic pulmonary fibrosis and cancer: do they really look similar?</article-title>
            <source>BMC Med</source>
            <year>2015</year>
            <month>Sep</month>
            <day>24</day>
            <volume>13</volume>
            <fpage>220</fpage>
            <pub-id pub-id-type="pmid">26399408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wind</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Freiwald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marzin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lotz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ebner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stopfer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dallinger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>1131</fpage>
            <page-range>1131-1147</page-range>
            <pub-id pub-id-type="pmid">31016670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bonella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Demedts</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coeck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pelling</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quaresma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lasky</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.</article-title>
            <source>Respir Res</source>
            <year>2015</year>
            <month>Sep</month>
            <day>24</day>
            <volume>16</volume>
            <fpage>116</fpage>
            <pub-id pub-id-type="pmid">26400368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>857</fpage>
            <page-range>857-865</page-range>
            <pub-id pub-id-type="pmid">28571476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Nintedanib</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>12</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29999921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mira-Avendano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2024</year>
            <season>Jan-Dec</season>
            <volume>18</volume>
            <fpage>17534666241266343</fpage>
            <pub-id pub-id-type="pmid">39113425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Nintedanib</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">31643465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Highland</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allanore</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Assassi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bourdin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>JHW</given-names>
              </name>
              <name>
                <surname>Hoffmann-Vold</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vonk</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gahlemann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clerisme-Beaty</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zoz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <collab>SENSCIS trial investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-106</page-range>
            <pub-id pub-id-type="pmid">33412120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ochi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ihara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Jul</month>
            <day>16</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>12080</fpage>
            <pub-id pub-id-type="pmid">32669649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ochi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ihara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Aug</month>
            <day>19</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>12062</fpage>
            <pub-id pub-id-type="pmid">31427707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sadoyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamakawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okuda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okudela</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwasawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takemura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Sep</month>
            <day>07</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>10811</fpage>
            <pub-id pub-id-type="pmid">28883482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Belperio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kitamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Molina-Molina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tschoepe</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coeck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lievens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.</article-title>
            <source>Respir Res</source>
            <year>2022</year>
            <month>Apr</month>
            <day>07</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <pub-id pub-id-type="pmid">35392908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inoue</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nangaku</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis&#x02029;.</article-title>
            <source>Clin Nephrol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-50</page-range>
            <pub-id pub-id-type="pmid">31699213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grze&#x0015b;k</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wo&#x0017a;niak-Wi&#x0015b;niewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x00142;a&#x0017c;ejewski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>G&#x000f3;rny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wo&#x00142;owiec</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Rogowicz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nowaczyk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Dec</month>
            <day>30</day>
            <volume>22</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33396592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tschoepe</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Luisetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schlenker-Herceg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hallmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.</article-title>
            <source>Eur Respir J</source>
            <year>2017</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">28526798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoon</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study.</article-title>
            <source>Respir Res</source>
            <year>2024</year>
            <month>Apr</month>
            <day>29</day>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>191</fpage>
            <pub-id pub-id-type="pmid">38685071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ameri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spallarossa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mercurio</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tocchetti</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Porto</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular safety of the tyrosine kinase inhibitor nintedanib.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>10</issue>
            <fpage>3690</fpage>
            <page-range>3690-3698</page-range>
            <pub-id pub-id-type="pmid">33620103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarzi-Puttini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Airoldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antivalle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Battellino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atzeni</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>33</volume>
            <issue>4 Suppl 91</issue>
            <fpage>S142</fpage>
            <page-range>S142-7</page-range>
            <pub-id pub-id-type="pmid">26339893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katzen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Raparia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Rademaker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dematte</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>e0117829</fpage>
            <pub-id pub-id-type="pmid">25689302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hansell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kolb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Selman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Maulf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Girard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schlenker-Herceg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Disse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <collab>INPULSIS Trial Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>May</month>
            <day>29</day>
            <volume>370</volume>
            <issue>22</issue>
            <fpage>2071</fpage>
            <page-range>2071-82</page-range>
            <pub-id pub-id-type="pmid">24836310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barr</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LeMoine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bakst</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>American translation, modification, and validation of the St. George's Respiratory Questionnaire.</article-title>
            <source>Clin Ther</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>1121</fpage>
            <page-range>1121-45</page-range>
            <pub-id pub-id-type="pmid">11048909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>&#x00160;terclov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mogulkoc</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lewandowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>H&#x000e1;jkov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Jovanovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tekavec-Trkanjec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Studnicka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stoeva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hejduk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Du&#x00161;ek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Suissa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Va&#x00161;&#x000e1;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <collab>EMPIRE registry</collab>
            </person-group>
            <article-title>The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.</article-title>
            <source>Respir Res</source>
            <year>2020</year>
            <month>Jan</month>
            <day>08</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">31915023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vancheri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kreuter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ryerson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Valeyre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grutters</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wiebe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stansen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Quaresma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stowasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wuyts</surname>
                <given-names>WA</given-names>
              </name>
              <collab>INJOURNEY Trial Investigators</collab>
            </person-group>
            <article-title>Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>197</volume>
            <issue>3</issue>
            <fpage>356</fpage>
            <page-range>356-363</page-range>
            <pub-id pub-id-type="pmid">28889759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivera-Ortega</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hayton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blaikley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.</article-title>
            <source>Ther Adv Respir Dis</source>
            <year>2018</year>
            <season>Jan-Dec</season>
            <volume>12</volume>
            <fpage>1753466618800618</fpage>
            <pub-id pub-id-type="pmid">30249169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishiyama</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kataoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arizono</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shiraki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kozu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kondoh</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis.</article-title>
            <source>ERJ Open Res</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">34435033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Bajpai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Whittle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Belcher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abdul Sultan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mamas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mallen</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease is a risk factor for ischaemic heart disease and myocardial infarction.</article-title>
            <source>Heart</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>106</volume>
            <issue>12</issue>
            <fpage>916</fpage>
            <page-range>916-922</page-range>
            <pub-id pub-id-type="pmid">32114515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nintedanib ameliorates oxidized low-density lipoprotein -induced inflammation and cellular senescence in vascular endothelial cells.</article-title>
            <source>Bioengineered</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>6196</fpage>
            <page-range>6196-6207</page-range>
            <pub-id pub-id-type="pmid">35236245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryerson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Arean</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Berkeley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carrieri-Kohlman</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Pantilat</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Landefeld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Depression is a common and chronic comorbidity in patients with interstitial lung disease.</article-title>
            <source>Respirology</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>525</fpage>
            <page-range>525-32</page-range>
            <pub-id pub-id-type="pmid">22221976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umemura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mitsuyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamakawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nochioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujimi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.</article-title>
            <source>Int J Infect Dis</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>108</volume>
            <fpage>454</fpage>
            <page-range>454-460</page-range>
            <pub-id pub-id-type="pmid">34048887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniels</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Treatment of idiopathic pulmonary fibrosis.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>668</fpage>
            <page-range>668-76</page-range>
            <pub-id pub-id-type="pmid">17195143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143222.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bengtson</surname>
                <given-names>LGS</given-names>
              </name>
              <name>
                <surname>Conoscenti</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Brekke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.</article-title>
            <source>J Med Econ</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>532</fpage>
            <page-range>532-540</page-range>
            <pub-id pub-id-type="pmid">35321616</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
